https://www.gsk.com/en-gb/media/press-releases/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint | GSK
GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.
phase iii study
https://www.biospace.com/ym-biosciences-reports-additional-results-from-nimotuzumab-phase-iii-study
YM BioSciences Reports Additional Results from NIMOTUZUMAB PHASE III Study - BioSpace
phase iii studyym biosciencesreportsadditionalresults
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive...
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable...
phase iii study
https://www.mdedge.com/content/acupuncture-improves-knee-oa-phase-iii-study
Acupuncture Improves Knee OA in Phase III Study | MDedge
phase iii studyacupunctureimproveskneeoa
https://www.prnewswire.com/news-releases/sylentis-initiates-a-phase-iii-study-for-the-treatment-of-dry-eye-syndrome-625693123.html
Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome
/PRNewswire/ -- The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational...
phase iii study
https://www.gsk.com/en-gb/media/press-releases/gsk-and-prosensa-announce-start-of-phase-iii-study-of-investigational-duchenne-muscular-dystrophy-medication/
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy...
GSK and Prosensa announced - first patient has commenced treatment in the Phase III study investigating GSK2402968 in ambulant boys with DMD
phase iii study
https://www.gene.com/media/statements/ps_110917
Genentech: Statements | Genentech Statement on Chroma, the Second Phase III Study for Lampalizumab
Read our formal press statements on significant topics and events.
phase iii studythe second
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-positive-phase-iii-study-investigating-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa/
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients...
GSK announces NEJM publication of phase III study investigating mepolizumab in patients with EGPA
phase iii study
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447&r=1
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive...
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable...
phase iii study
https://www.biospace.com/janssen-pharmaceutica-n-v-announces-pivotal-phase-iii-study-results-for-investigational-darunavir-based-single-tablet-regimen-for-the-treatment-of-hi
Janssen Pharmaceutica N.V. Announces Pivotal Phase III Study Results For Investigational...
phase iii studyjanssen pharmaceutica
https://www.straitstimes.com/world/europe/bayer-cancels-asundexian-phase-iii-study-program
Bayer cancels asundexian phase III study programme | The Straits Times
Nov 12, 2024 - Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa)...
phase iii studythe straitsbayercancelsasundexian
https://www.pasteur.fr/en/treatment-cutaneous-leishmaniasis-study-phase-iii-shows-antibiotic-cream-has-high-cure-rate-few-side?language=fr
Treatment of Cutaneous Leishmaniasis: Study of Phase III Shows Antibiotic Cream Has High Cure Rate,...
Oct 14, 2016 - An international research partnership from Tunisia, France and the United States has demonstrated a high cure rate and remarkably few side effects in treating...
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-overall-survival-results-from-phase-iii-combi-d-study-of-dabrafenib-tafinlar-and-trametinib-mekinist-combination/
GSK announces positive overall survival results from phase III COMBI-d study of dabrafenib...
GSK today announced overall survival results from COMBI-d which demonstrate a statistically significant reduction in the risk of death
https://www.insidermonkey.com/blog/positive-results-reported-for-ocular-therapeutix-inc-ocul-dextenza-following-phase-iii-study-567226/
Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study -...
Positive results for the Phase III study meant to test the experiences of patients using the eye insert known as Dextenza to relieve pain in a post-surgical...
https://www.roche.com/media/releases/med-cor-2020-12-10
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the...
People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant...
https://www.mskcc.org/cancer-care/clinical-trials/21-044
A Phase III Randomized Study Assessing the Addition of Abiraterone Acetate with Prednisone and...
Full Title Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer...
https://www.prnewswire.com/news-releases/taihos-tas-102-meets-primary-endpoint-of-improving-overall-survival-in-phase-iii-terra-study-in-asian-patients-with-refractory-metastatic-colorectal-cancer-300244624.html
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in...
/PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. of Tokyo announced on April 1 results from its Phase III TERRA study on its oral combination anticancer drug...